(Alliance News) - Shares in Evgen Pharma PLC rose on Friday after it said preclinical data showed its SFX-01 composite inhibits SHP2, a protein associated with a number of different cancer types.
Shares In Evgen Pharma were trading 4.4% higher at 12.00 pence each on Friday morning in London. The stock is up 16% so far in 2021.
SFX-01 is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. SHP2 is a non-receptor protein tyrosine phosphatase that is associated with breast cancer, leukaemia, lung cancer, liver cancer, gastric cancer, laryngeal cancer, oral cancer and other cancer types.
The Liverpool-based clinical stage drug development company said in-vitro and in-vivo data demonstrates that SFX-01 modifies SHP2, inhibiting its phosphatase activity.
"This exciting data provides another pathway through which SFX-01 may be a valuable anti-cancer agent in addition to its effects on the STAT3 pathway, thought to be the principal mechanism of action in metastatic breast cancer," Evgen Pharma.
Evgen Pharma is conducting further preclinical work in cancer models, and data will be announced soon.
This comes after the company on Thursday saying it has seen "highly positive" data for SFX-01 in pre-clinical models of glioma and glioblastoma, which are types of brain tumours, noting data shows tumour shrinkage and significantly extended survival times. It added it plans to expand upon the pre-clinical data and start the process of designing a Phase 2 clinical trial.
By Ife Taiwo; ifetaiwo@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Evgen Pharma (EVG)